| Amanda Duboys, OT | |
|
601 E Hampden Ave Ste 500, Englewood, CO 80113-2771 | |
| (917) 903-5620 | |
| Not Available |
| Full Name | Amanda Duboys |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 21 Years |
| Location | 601 E Hampden Ave Ste 500, Englewood, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942397815 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 0129791 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uchealth Community Services | 5395024905 | 98 |
News Archive
Paloma T. Gonzalez-Bellido, a postdoctoral scientist at the Marine Biological Laboratory and her colleagues have been awarded a 2012 Cozzarelli Prize by the editorial board of the Proceedings of the National Academy of Sciences.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.
US experts have called for more selective and cautious opioid prescribing for chronic noncancer pain, because of concerns over misuse of the drugs and continued uncertainty over when and for how long they should be prescribed.
› Verified 5 days ago
| Provider Name | Uchealth Community Services |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1841740693 PECOS PAC ID: 5395024905 Enrollment ID: O20161122000429 |
News Archive
Paloma T. Gonzalez-Bellido, a postdoctoral scientist at the Marine Biological Laboratory and her colleagues have been awarded a 2012 Cozzarelli Prize by the editorial board of the Proceedings of the National Academy of Sciences.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.
US experts have called for more selective and cautious opioid prescribing for chronic noncancer pain, because of concerns over misuse of the drugs and continued uncertainty over when and for how long they should be prescribed.
› Verified 5 days ago
| Provider Name | Orthopedic Centers Of Colorado |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1801339502 PECOS PAC ID: 2365714540 Enrollment ID: O20170823001317 |
News Archive
Paloma T. Gonzalez-Bellido, a postdoctoral scientist at the Marine Biological Laboratory and her colleagues have been awarded a 2012 Cozzarelli Prize by the editorial board of the Proceedings of the National Academy of Sciences.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.
US experts have called for more selective and cautious opioid prescribing for chronic noncancer pain, because of concerns over misuse of the drugs and continued uncertainty over when and for how long they should be prescribed.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Duboys, OT 601 E Hampden Ave Ste 500, Englewood, CO 80113-2771 Ph: (303) 744-7078 | Amanda Duboys, OT 601 E Hampden Ave Ste 500, Englewood, CO 80113-2771 Ph: (917) 903-5620 |
News Archive
Paloma T. Gonzalez-Bellido, a postdoctoral scientist at the Marine Biological Laboratory and her colleagues have been awarded a 2012 Cozzarelli Prize by the editorial board of the Proceedings of the National Academy of Sciences.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.
Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.
US experts have called for more selective and cautious opioid prescribing for chronic noncancer pain, because of concerns over misuse of the drugs and continued uncertainty over when and for how long they should be prescribed.
› Verified 5 days ago
Whitney Oyster, Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 175 Inverness Dr W Ste 200, Englewood, CO 80112 Phone: 303-694-3333 | |
Ms. Gloria Jean Viglione, O.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 701 E Hampden Ave, Suite 330, Englewood, CO 80113 Phone: 303-497-1724 | |
Miss Kristina Anderson, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 701 E Hampden Ave, Suite 330, Englewood, CO 80113 Phone: 303-806-7421 | |
Lynn Vosbeek, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6065 S Quebec St, Englewood, CO 80111 Phone: 184-442-2266 | |
Kara Greenfield Burks, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 175 Inverness Dr W Ste 100, Englewood, CO 80112 Phone: 303-694-3333 Fax: 303-694-9666 | |
Kerry Goudy, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4480 S Lafayette St, Englewood, CO 80113 Phone: 720-272-2754 | |
Laura Louise Koenig, OTR Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 601 E Hampden Ave Ste 500, Englewood, CO 80113 Phone: 303-744-7078 |